Johns Hopkins Medicine News

The enzyme machine that translates a cell’s DNA code into the proteins of life is nothing if not an editorial perfectionist.

Pterosaurs have long suffered an identity crisis. Pop culture heedlessly — and wrongly — lumps these extinct flying lizards in with dinosaurs. Even paleontologists assumed that because the creatures flew, they were birdlike in many ways, such as using only two legs to take flight.

Digitalis-based drugs like digoxin have been used for centuries to treat patients with irregular heart rhythms and heart failure and are still in use today. In the Dec. 16 issue of the Proceedings of the National Academy of Sciences, researchers at the Johns Hopkins University School of Medicine now report that this same class of drugs may hold new promise as a treatment for cancer. This finding emerged through a search for existing drugs that might slow or stop cancer progression.

Johns Hopkins and other researchers report what is believed to be the first direct evidence in lab animals that the erectile dysfunction drug sildenafil amplifies the effects of a heart-protective protein.

A team of Johns Hopkins neuroscientists has worked out how some newly discovered light sensors in the eye detect light and communicate with the brain.

The hormone deprivation therapy that prostate cancer patients often take gives them only a temporary fix, with tumors usually regaining their hold within a couple of years. Now, researchers at Johns Hopkins have discovered critical differences in the hormone receptors on prostate cancer cells in patients who no longer respond to this therapy.

When researchers look inside human cancer cells for the whereabouts of an important tumor-suppressor, they often catch the protein playing hooky, lolling around in cellular broth instead of muscling its way out to the cells’ membranes and foiling cancer growth.